MEI Pharma (MEIP) says Yale School of Medicine's Ayesha Alvero presented data showing the company's ME-344 mitichondrial inhibitor "decreased tumor burden and delayed recurrence" in a pre-clinical in vivo recurrence model. The shares rose +2.24% during regular trading.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs